Page last updated: 2024-12-07

d-glucitol, 6-o-alpha-d-glucopyranosyl-, mixture with 1-o-alpha-d-glucopyranosyl-d-mannitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Palatinit: mixture of 1,6-mannitol glucopyranoside & 1,6-sorbitol glucopyranoside that affects de- and remineralization; non-cariogenic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-O-alpha-D-glucopyranosyl-D-mannitol : A 1-O-D-glucopyranosyl-D-mannitol that has alpha configuration at the anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID88735
CHEMBL ID3187473
CHEBI ID150326
CHEBI ID192265
SCHEMBL ID154031
MeSH IDM0066784

Synonyms (42)

Synonym
palatinit
ccris 3698
d-glucitol, 6-o-alpha-d-glucopyranosyl-, mixt. with 1-o-alpha-d-glucopyranosyl-d-mannitol
GPM ,
1-o-alpha-d-glucopyranosyl-d-mannitol
20942-99-8
570FC73A-80F5-464F-B47E-B9B4CC544121
wurcs=2.0/2,2,1/[h1122h][a2122h-1a_1-5]/1-2/a6-b1
CHEBI:150326
CHEBI:192265
(2r,3r,4r,5r)-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,4,5-pentol
NCGC00248874-01
d-mannitol, 1-o-alpha-d-glucopyranosyl-
einecs 244-122-4
g97p6s66e9 ,
unii-g97p6s66e9
s870p55o2w ,
galeniq 980
unii-s870p55o2w
isomaltidex
hsdb 7969
d-mannitol, 1-o-.alpha.-d-glucopyranosyl-
SCHEMBL154031
1,1-gpm
6-o-.alpha.-d-glucopyranosyl-d-mannitol
1-o-.alpha.-d-glucopyranosyl-d-mannitol
glucosylmannitol
glucosylmannitol [mi]
W-109182
CHEMBL3187473
1-o-(a-glucopyranosyl)-d-mannitol dihydrate
DTXSID60872321
6-o-a-d-glucopyranosyl-d-glucitol
A919358
(2r,3r,4r,5r)-6-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)hexane-1,2,3,4,5-pentaol
(2r,3r,4r,5r)-6-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)hexane-1,2,3,4,5-pentaol
Q412068
SERLAGPUMNYUCK-DCUALPFSSA-N
A14329
A914114
6-o-a-d-glucopyranosyl-d-mannitol
PD117933

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The possible adverse effects of restricted feeding were studied in an additional group (food intake less than 80% of the control values)."( Embryotoxicity/teratogenicity of isomalt in rats and rabbits.
Koëter, HB; van Marwijk, MW; Waalkens-Berendsen, DH, 1990
)
0.28
" Isomalt appeared to have slight toxic effects in the dams of the Bay FB:30 strain but no toxicity in the offspring."( Developmental toxicity of isomalt in rats.
Koëter, HB; Renhof, M; Schlüter, G; Waalkens-Berendsen, DH, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
"For the sake of metabolic insight into the fate of the sugar substitute Palatinit, its two components D-glucosyl-alpha (1 leads to 1)-D-mannitol and D-glucosyl-alpha (1 leads to 6)-D-glucitol [D-glucosyl-alpha-(1 leads to 6)-D-sorbitol] were assayed for glucose bioavailability by the procedure of Karimzadegan et al."( Bioavailability of glucose from Palatinit.
Ziesenitz, SC, 1983
)
0.27
"The bioavailability of hydrochlorothiazide (HCT) from moulded isomalt-based tablets was evaluated after oral administration of 50 mg HCT to healthy volunteers as an oral moulded tablet and as a lozenge, in comparison with a conventional tablet formulation (Dichlotride 50 mg)."( Bioavailability of hydrochlorothiazide from isomalt-based moulded tablets.
Ndindayino, F; Remon, JP; Van den Mooter, G; Vervaet, C, 2002
)
0.31
" Poorly absorbed sweet tastants (TIM), which probably expose a greater length of gut to nutrients, result in delayed GLP-1 secretion but not in delayed GIP release."( Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans.
Bellon, M; Bound, MJ; Checklin, HL; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Young, RL; Zhao, BR, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
"This study investigated a sieve classification method for evaluating carrier materials and particle size fractions, which could be a valuable tool in the early development of pharmaceutical dosage forms containing low-dose interactive mixtures."( Evaluation of a sieve classification method for characterization of low-dose interactive mixtures.
Bredenberg, S; Dahlgren, A; Mattsson, S,
)
0.13
"Isomalt is a sugar alcohol used as an excipient in commercially available solid oral dosage forms."( Physical Stability of Freeze-Dried Isomalt Diastereomer Mixtures.
Barnsley, JE; Bøtker, JP; Fraser-Miller, SJ; Gordon, KC; Heljo, VP; Juppo, AM; Koskinen, AK; Strachan, CJ, 2016
)
0.43
"There has been limited research done on the downstream processing of nanosuspensions into solid oral dosage forms."( Downstream drug product processing of itraconazole nanosuspension: Factors influencing tablet material properties and dissolution of compacted nanosuspension-layered sugar beads.
Low, A; Möschwitzer, JP; Parmentier, J; Tan, EH, 2017
)
0.46
"The development of orodispersible mini-tablets (ODMTs) for paediatric use has gained importance within recent years as European authorities set up regulations for developing suitable and palatable dosage forms for paediatric patients."( New orodispersible mini-tablets for paediatric use - A comparison of isomalt with a mannitol based co-processed excipient.
Breitkreutz, J; Luhn, O; Lura, A; Suarez Gonzales, J, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
1-O-D-glucopyranosyl-D-mannitolA glycosyl alditol consistion of a D-glucopyranose and a D-manitol residue joined in sequence by a (1->1) glycosidic bond.
(2xi)-6-O-alpha-D-glucopyranosyl-D-arabino-hexitolA glycosyl alditol consisting of alpha-D-glucopyranose and (2xi)-D-arabino-hexitol residues joined in sequence by a (1->1) glycosidic bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (31.58)18.7374
1990's13 (17.11)18.2507
2000's12 (15.79)29.6817
2010's24 (31.58)24.3611
2020's3 (3.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.06 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (18.52%)5.53%
Reviews1 (1.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (80.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]